IL116406A0 - Tricyclic substituted hexahydrobenz (e) isoindole alpha-1 adrenergic antagonists - Google Patents
Tricyclic substituted hexahydrobenz (e) isoindole alpha-1 adrenergic antagonistsInfo
- Publication number
- IL116406A0 IL116406A0 IL11640695A IL11640695A IL116406A0 IL 116406 A0 IL116406 A0 IL 116406A0 IL 11640695 A IL11640695 A IL 11640695A IL 11640695 A IL11640695 A IL 11640695A IL 116406 A0 IL116406 A0 IL 116406A0
- Authority
- IL
- Israel
- Prior art keywords
- alpha
- adrenergic antagonists
- tricyclic substituted
- isoindole
- substituted hexahydrobenz
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/379,823 US5521181A (en) | 1995-01-27 | 1995-01-27 | Bicyclic substituted hexahydrobenz[e]isoindole α-1 adrenergic antagonists |
| US08/465,476 US5792767A (en) | 1995-01-27 | 1995-06-05 | Bicyclic substituted hexahydrobenz e! isoindole alpha-1 adrenergic antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL116406A0 true IL116406A0 (en) | 1996-12-15 |
Family
ID=27008783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL11640695A IL116406A0 (en) | 1995-01-27 | 1996-12-15 | Tricyclic substituted hexahydrobenz (e) isoindole alpha-1 adrenergic antagonists |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US5792767A (el) |
| EP (1) | EP0805812B1 (el) |
| JP (1) | JPH11501616A (el) |
| KR (1) | KR19980701780A (el) |
| AT (1) | ATE202107T1 (el) |
| AU (1) | AU694611B2 (el) |
| CA (1) | CA2210966A1 (el) |
| DE (1) | DE69613347T2 (el) |
| DK (1) | DK0805812T3 (el) |
| ES (1) | ES2159721T3 (el) |
| GR (1) | GR3036560T3 (el) |
| IL (1) | IL116406A0 (el) |
| MX (1) | MX9705675A (el) |
| PT (1) | PT805812E (el) |
| WO (1) | WO1996022991A1 (el) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6133275A (en) * | 1998-05-06 | 2000-10-17 | Abbott Laboratories | 3-phenylpyrrolidine alpha-1 adrenergic compounds |
| US6930101B1 (en) | 1999-05-17 | 2005-08-16 | The Regents Of The University Of California | Thiazolopyrimidines useful as TNFα inhibitors |
| HN2000000051A (es) * | 1999-05-19 | 2001-02-02 | Pfizer Prod Inc | Derivados heterociclicos utiles como agentes anticancerosos |
| US6420407B1 (en) | 1999-09-16 | 2002-07-16 | Gerald Horn | Ophthalmic formulation which modulates dilation |
| US20020082288A1 (en) * | 1999-09-16 | 2002-06-27 | Gerald Horn | Ophthalmic formulations comprising an imidazoline |
| US8889112B2 (en) * | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| US6730065B1 (en) * | 2000-09-15 | 2004-05-04 | Ocularis Pharma, Inc. | Night vision composition |
| US7273868B2 (en) | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
| KR100711042B1 (ko) * | 2000-04-28 | 2007-04-24 | 다나베 세이야꾸 가부시키가이샤 | 환상 화합물 |
| US20060211753A1 (en) * | 2000-11-03 | 2006-09-21 | Ocularis Pharma, Inc. | Method and composition which reduces stimulation of muscles which dilate the eye |
| WO2002064598A1 (en) * | 2001-02-14 | 2002-08-22 | Warner-Lambert Company Llc | Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors |
| JP4166991B2 (ja) | 2001-02-26 | 2008-10-15 | 田辺三菱製薬株式会社 | ピリドピリミジンまたはナフチリジン誘導体 |
| US10022078B2 (en) | 2004-07-13 | 2018-07-17 | Dexcom, Inc. | Analyte sensor |
| AU2003281170A1 (en) * | 2002-07-17 | 2004-02-02 | Warner-Lambert Company Llc | Pharmaceutical compostions comprising an allosteric carboxylic inhibitor of matrix metalloproteinase-13 and a selective inhibitor of cyclooxygenase-2 |
| US7022850B2 (en) | 2003-05-22 | 2006-04-04 | Bristol-Myers Squibb Co. | Bicyclicpyrimidones and their use to treat diseases |
| US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
| US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
| US7654956B2 (en) | 2004-07-13 | 2010-02-02 | Dexcom, Inc. | Transcutaneous analyte sensor |
| BRPI0514390A (pt) | 2004-08-18 | 2008-06-10 | Astrazeneca Ab | enanciÈmero de um composto ou um sal farmacêuticamente aceitável ou um éster hidrolisável in vivo do mesmo, uso do mesmo, métodos para o tratamento de cáncer, para produzir um efeito inibidor de eg5 em um animal de sangue quente e para tratar doenças, e, composição farmacêutica |
| DE102008022221A1 (de) | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| US20100291151A1 (en) * | 2009-04-21 | 2010-11-18 | Auspex Pharmaceuticals, Inc. | 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor |
| US8541404B2 (en) * | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
| US9089560B2 (en) | 2013-02-01 | 2015-07-28 | Ocularis Pharma, Llc | Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance |
| DK2950648T3 (da) | 2013-02-01 | 2019-12-02 | Ocuphire Pharma Inc | Vandige oftalmiske opløsninger af phentolamin og medicinske anvendelser deraf |
| KR20210096096A (ko) | 2018-10-26 | 2021-08-04 | 오큐파이어 파마, 인크. | 노안, 산동, 및 기타 안구 장애의 치료를 위한 방법 및 조성물 |
| JPWO2021039660A1 (el) * | 2019-08-29 | 2021-03-04 | ||
| CN115368310A (zh) | 2021-05-18 | 2022-11-22 | 奥库菲尔医药公司 | 合成甲磺酸酚妥拉明的方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU560459B2 (en) * | 1982-06-01 | 1987-04-09 | Abbott Laboratories | Tetrahydro-benzo(e) isoindolines |
| CA1337425C (en) * | 1988-01-15 | 1995-10-24 | Robert Edward Zelle | Substituted (n-ethylamino)methyl-1,2,3,4- tetrahydronaphthalene compounds having alpha-2 adrenergic antagonist activity |
| US5089519A (en) * | 1988-01-15 | 1992-02-18 | Abbott Laboratories | Aminomethyl-chroman compounds |
| AU639615B2 (en) * | 1990-10-09 | 1993-07-29 | Otsuka Pharmaceutical Co., Ltd. | Pyrimidine derivative, production thereof, and androgen inhibitor |
| US5158953A (en) * | 1991-08-13 | 1992-10-27 | National Science Council | 2-substituted methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-ones (thiones), the preparation and use thereof |
| US5288749A (en) * | 1991-12-20 | 1994-02-22 | Abbott Laboratories | Tertiary and secondary amines as alpha-2 antagonists and serotonin uptake inhibitors |
| US5403847A (en) * | 1992-11-13 | 1995-04-04 | Synaptic Pharmaceutical Corporation | Use of α1C specific compounds to treat benign prostatic hyperlasia |
| US5521181A (en) * | 1995-01-27 | 1996-05-28 | Abbott Laboratories | Bicyclic substituted hexahydrobenz[e]isoindole α-1 adrenergic antagonists |
-
1995
- 1995-06-05 US US08/465,476 patent/US5792767A/en not_active Expired - Fee Related
-
1996
- 1996-01-11 WO PCT/US1996/000178 patent/WO1996022991A1/en active IP Right Grant
- 1996-01-11 ES ES96903364T patent/ES2159721T3/es not_active Expired - Lifetime
- 1996-01-11 AU AU47473/96A patent/AU694611B2/en not_active Ceased
- 1996-01-11 DE DE69613347T patent/DE69613347T2/de not_active Expired - Fee Related
- 1996-01-11 EP EP96903364A patent/EP0805812B1/en not_active Expired - Lifetime
- 1996-01-11 MX MX9705675A patent/MX9705675A/es unknown
- 1996-01-11 KR KR1019970705177A patent/KR19980701780A/ko active IP Right Grant
- 1996-01-11 CA CA002210966A patent/CA2210966A1/en not_active Abandoned
- 1996-01-11 DK DK96903364T patent/DK0805812T3/da active
- 1996-01-11 JP JP8522872A patent/JPH11501616A/ja active Pending
- 1996-01-11 PT PT96903364T patent/PT805812E/pt unknown
- 1996-01-11 AT AT96903364T patent/ATE202107T1/de not_active IP Right Cessation
- 1996-12-15 IL IL11640695A patent/IL116406A0/xx unknown
-
2001
- 2001-09-06 GR GR20010401414T patent/GR3036560T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0805812A1 (en) | 1997-11-12 |
| EP0805812B1 (en) | 2001-06-13 |
| DK0805812T3 (da) | 2001-09-17 |
| ATE202107T1 (de) | 2001-06-15 |
| ES2159721T3 (es) | 2001-10-16 |
| PT805812E (pt) | 2001-11-30 |
| JPH11501616A (ja) | 1999-02-09 |
| KR19980701780A (ko) | 1998-06-25 |
| AU4747396A (en) | 1996-08-14 |
| AU694611B2 (en) | 1998-07-23 |
| DE69613347D1 (de) | 2001-07-19 |
| CA2210966A1 (en) | 1996-08-01 |
| DE69613347T2 (de) | 2002-04-18 |
| MX9705675A (es) | 1997-10-31 |
| WO1996022991A1 (en) | 1996-08-01 |
| GR3036560T3 (en) | 2001-12-31 |
| US5792767A (en) | 1998-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL116405A0 (en) | Tricyclic substituted hexahydrobenz (e) isoindole alpha-1 adrenergic antagonists | |
| IL116406A0 (en) | Tricyclic substituted hexahydrobenz (e) isoindole alpha-1 adrenergic antagonists | |
| MX9705313A (es) | Benzazepinas triciclicas antagonistas de la vasopresina. | |
| MY132229A (en) | Indole derivatives as 5-ht receptor antagonist | |
| IE873548L (en) | Peptidylaminodiols | |
| MXPA99000214A (es) | Antagonistas de la vasopresina, a base de benzazepinas triciclicas. | |
| UA39168C2 (uk) | Фторалкоксифенільні похідні піперидину або хінуклідину, що є антагоністами речовини p і фармацевтична композиція на їх основі | |
| CA2098176A1 (en) | Angiotensin ii receptor blocking compositions | |
| MX9705415A (es) | Antagonsitas de vasopresina triciclicos de benzazepina. | |
| CY2260B1 (en) | Benzopyranopyrrole and benzopyranopyridine alpha-1adrenergic compounds | |
| ATE252586T1 (de) | 8-substituierte-9h-1,3-dioxolo/4,5-h//2, 3/benzodiazepin derivate als ampa/kainate- rezeptor-hemmer | |
| AU5644296A (en) | Novel heterocyclic chemistry | |
| MX9708557A (es) | Nuevo uso farmacologico de los antagonistas del receptor aii. | |
| MY118704A (en) | Process for preparation of eprosartan | |
| GR3030506T3 (en) | 1-azaadamantane derivatives as 5-ht agonists or antagonists. | |
| EP0804186A4 (en) | INDOLDITERPEN ALKALOIDS | |
| YU60803A (sh) | Upotreba antagonista gal3 receptora u lečenju depresije i/ili uznemirenosti i jedinjenja korisna u tim postupcima | |
| BR9713682A (pt) | Compostos alfa - 1 adrenergicos de benzopiranopirrol e benzopiranopiridina | |
| CA2210631A1 (en) | Tricyclic benzazepine vasopressin antagonists | |
| YU24501A (sh) | Estri od(+)-alfa-(2,3-dimetoksifenil)-1-(2-(4-fluorofenil) etil)-4-piperidinmetanola i njihovo korišćenje kao prolekova od 5ht2a receptor antagonista mdl 110,907 |